Global Genitourinary Drugs

Genitourinary Drugs Comprehensive Study by Type (Urologicals, Hormonal Therapy, Gynecological, Anti-infectives), Drug Type (Hormonal Therapy, Targeted Drugs, Urinary Antispasmodics, Uterine relaxants, Others), Disease Type (Urinary Tract Infections, STD, Haematuria, Urinary Incontinence, Erectile dysfunction, Others), Distribution Chanel (Direct, Indirect), Cancer Type (Colorectal, Kidney, Prostate, Cervical), Application (Hospitals & Clinics, Oncological Research Centres) Players and Region - Global Market Outlook to 2026

Genitourinary Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Genitourinary Drugs Market Scope
Genitourinary drugs are mainly used for the treat of numerous type of urogenital cancers and infections. This cancers are related to kidney, urethra, ureters and urinary bladder. This drugs are used to kill proliferating cancer cells. Spread of cancer is mainly occur by the rapid outburst of abnormal cells apart from their boundaries. Urinary tract infections are mainly caused by poor hygienic care and certain microorganisms. Changing lifestyle, rising number of geriatric population leads to rise in prevalence of urogenital cancer across the globe. Colorectal cancer contributed to the largest new incidence cases across the globe. Thus, with rising incidence cases, the demand for genitourinary drugs has been raised. Governments & research organisations across the globe are focusing to spread awareness regarding cancer treatments majorly in African countries. Thus, pharmaceutical companies are focusing on providing new products lines for the treatment of advanced cancers and wide range of urinary infections which is anticipated to drive the market growth over forecast period.

The Genitourinary Drugs market study is segmented by Type (Urologicals, Hormonal Therapy, Gynecological and Anti-infectives) and major geographies with country level break-up.

Novartis AG (Switzerland), Bristol-Myers Squibb (United States), Johnson & Johnson (United States), Pfizer Inc. (United States), Merck & Co., Inc. (United States), Hoffmann-La Roche Ltd. (United States), Astra Zeneca (United Kingdom), AbbVie Inc. (United States), Celgene (United States), Eli Lilly & Co (United States), Cadila Healthcare Limited (India), Dr. Reddy’s Laboratories Ltd. (India), Amgen (United States) and AQVIDA GmbH (Germany) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Genitourinary Drugs market by Type, Application and Region.

On the basis of geography, the market of Genitourinary Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
The market of genitourinary drugs is expected to grow with rising prevalence of urinary tract infections and cancers. Several companies are operating in the market to provide genitourinary drugs for the treatment of wide range of infections. The market is highly fragmented with the presence of number of market players. They are gaining attention owing to raised demand. They are taking certain strategic initiatives with new entrants to expand their existing portfolio.
In November 2019, Shionogi & Co., Ltd. has recived FDA approval for cefiderocol to treat complicated urinary tract infections (cUTI), pyelonephritis. This infection is caused by susceptible gram-negative microorganisms. With this approval, company is able to provide treatment for wide range of urinary tract infections caused by gram negative microorganism.
BLA- A biologics license application (BLA) is defined by the U.S. Food and Drug Administration (FDA). It is regulated under 21 CFR 600 – 680. The biologics license application is a permission to introduce, a biologic product into interstate commerce (21 CFR 601.2).

Market Trend
  • Pharmaceutical Companies Conducting Massive R&D Activities for Development of the New Product Lines to Treat Advanced Urogenital Cancers

Market Drivers
  • Growing Expenditure of Pharmaceutical Industry
  • Increasing Urogenital Cancer Incidence across the Globe
  • Rising Government Initiatives to Increase Awareness Regarding Advanced Treatments

Opportunities
  • Government Funding’s For Oncological Research Centers to Develop Novel Drugs
  • Rising Approvals for Drugs to Advanced Colorectal Cancer Has Created Growth Opportunities for Market

Restraints
  • Huge Treatment Cost of Advanced Urogenital Cancer May Restrain Its Demand
  • Side Effects Associated With Drugs Expected To Hamper Its Demand
  • Straighten Regulatory Norms

Challenges
  • Huge Requirement of Investments for Drug Developments


Key Target Audience
The market of genitourinary drugs is expected to grow with rising prevalence of urinary tract infections and cancers. Several companies are operating in the market to provide genitourinary drugs for the treatment of wide range of infections. The market is highly fragmented with the presence of number of market players. They are gaining attention owing to raised demand. They are taking certain strategic initiatives with new entrants to expand their existing portfolio

Report Objectives / Segmentation Covered

By Type
  • Urologicals
  • Hormonal Therapy
  • Gynecological
  • Anti-infectives
By Drug Type
  • Hormonal Therapy
  • Targeted Drugs
  • Urinary Antispasmodics
  • Uterine relaxants
  • Others

By Disease Type
  • Urinary Tract Infections
  • STD
  • Haematuria
  • Urinary Incontinence
  • Erectile dysfunction
  • Others

By Distribution Chanel
  • Direct
  • Indirect

By Cancer Type
  • Colorectal
  • Kidney
  • Prostate
  • Cervical

By Application
  • Hospitals & Clinics
  • Oncological Research Centres

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Expenditure of Pharmaceutical Industry
      • 3.2.2. Increasing Urogenital Cancer Incidence across the Globe
      • 3.2.3. Rising Government Initiatives to Increase Awareness Regarding Advanced Treatments
    • 3.3. Market Challenges
      • 3.3.1. Huge Requirement of Investments for Drug Developments
    • 3.4. Market Trends
      • 3.4.1. Pharmaceutical Companies Conducting Massive R&D Activities for Development of the New Product Lines to Treat Advanced Urogenital Cancers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Genitourinary Drugs, by Type, Drug Type, Disease Type, Distribution Chanel, Cancer Type , Application and Region (value and volume ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Genitourinary Drugs (Value)
      • 5.2.1. Global Genitourinary Drugs by: Type (Value)
        • 5.2.1.1. Urologicals
        • 5.2.1.2. Hormonal Therapy
        • 5.2.1.3. Gynecological
        • 5.2.1.4. Anti-infectives
      • 5.2.2. Global Genitourinary Drugs by: Application (Value)
        • 5.2.2.1. Hospitals & Clinics
        • 5.2.2.2. Oncological Research Centres
      • 5.2.3. Global Genitourinary Drugs by: Drug Type (Value)
        • 5.2.3.1. Hormonal Therapy
        • 5.2.3.2. Targeted Drugs
        • 5.2.3.3. Urinary Antispasmodics
        • 5.2.3.4. Uterine relaxants
        • 5.2.3.5. Others
      • 5.2.4. Global Genitourinary Drugs by: Disease Type (Value)
        • 5.2.4.1. Urinary Tract Infections
        • 5.2.4.2. STD
        • 5.2.4.3. Haematuria
        • 5.2.4.4. Urinary Incontinence
        • 5.2.4.5. Erectile dysfunction
        • 5.2.4.6. Others
      • 5.2.5. Global Genitourinary Drugs by: Distribution Chanel (Value)
        • 5.2.5.1. Direct
        • 5.2.5.2. Indirect
      • 5.2.6. Global Genitourinary Drugs by: Application (Value)
        • 5.2.6.1. Hospitals & Clinics
        • 5.2.6.2. Oncological Research Centres
      • 5.2.7. Global Genitourinary Drugs Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Genitourinary Drugs (Volume)
      • 5.3.1. Global Genitourinary Drugs by: Type (Volume)
        • 5.3.1.1. Urologicals
        • 5.3.1.2. Hormonal Therapy
        • 5.3.1.3. Gynecological
        • 5.3.1.4. Anti-infectives
      • 5.3.2. Global Genitourinary Drugs by: Application (Volume)
        • 5.3.2.1. Hospitals & Clinics
        • 5.3.2.2. Oncological Research Centres
      • 5.3.3. Global Genitourinary Drugs by: Drug Type (Volume)
        • 5.3.3.1. Hormonal Therapy
        • 5.3.3.2. Targeted Drugs
        • 5.3.3.3. Urinary Antispasmodics
        • 5.3.3.4. Uterine relaxants
        • 5.3.3.5. Others
      • 5.3.4. Global Genitourinary Drugs by: Disease Type (Volume)
        • 5.3.4.1. Urinary Tract Infections
        • 5.3.4.2. STD
        • 5.3.4.3. Haematuria
        • 5.3.4.4. Urinary Incontinence
        • 5.3.4.5. Erectile dysfunction
        • 5.3.4.6. Others
      • 5.3.5. Global Genitourinary Drugs by: Distribution Chanel (Volume)
        • 5.3.5.1. Direct
        • 5.3.5.2. Indirect
      • 5.3.6. Global Genitourinary Drugs by: Application (Volume)
        • 5.3.6.1. Hospitals & Clinics
        • 5.3.6.2. Oncological Research Centres
      • 5.3.7. Global Genitourinary Drugs Region
        • 5.3.7.1. South America
          • 5.3.7.1.1. Brazil
          • 5.3.7.1.2. Argentina
          • 5.3.7.1.3. Rest of South America
        • 5.3.7.2. Asia Pacific
          • 5.3.7.2.1. China
          • 5.3.7.2.2. Japan
          • 5.3.7.2.3. India
          • 5.3.7.2.4. South Korea
          • 5.3.7.2.5. Taiwan
          • 5.3.7.2.6. Australia
          • 5.3.7.2.7. Rest of Asia-Pacific
        • 5.3.7.3. Europe
          • 5.3.7.3.1. Germany
          • 5.3.7.3.2. France
          • 5.3.7.3.3. Italy
          • 5.3.7.3.4. United Kingdom
          • 5.3.7.3.5. Netherlands
          • 5.3.7.3.6. Rest of Europe
        • 5.3.7.4. MEA
          • 5.3.7.4.1. Middle East
          • 5.3.7.4.2. Africa
        • 5.3.7.5. North America
          • 5.3.7.5.1. United States
          • 5.3.7.5.2. Canada
          • 5.3.7.5.3. Mexico
  • 6. Genitourinary Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hoffmann-La Roche Ltd. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Astra Zeneca (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AbbVie Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Celgene (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly & Co (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Cadila Healthcare Limited (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Dr. Reddy’s Laboratories Ltd. (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Amgen (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. AQVIDA GmbH (Germany)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global Genitourinary Drugs Sale, by Type, Drug Type, Disease Type, Distribution Chanel, Cancer Type , Application and Region (value and volume ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Genitourinary Drugs (Value)
      • 7.2.1. Global Genitourinary Drugs by: Type (Value)
        • 7.2.1.1. Urologicals
        • 7.2.1.2. Hormonal Therapy
        • 7.2.1.3. Gynecological
        • 7.2.1.4. Anti-infectives
      • 7.2.2. Global Genitourinary Drugs by: Application (Value)
        • 7.2.2.1. Hospitals & Clinics
        • 7.2.2.2. Oncological Research Centres
      • 7.2.3. Global Genitourinary Drugs by: Drug Type (Value)
        • 7.2.3.1. Hormonal Therapy
        • 7.2.3.2. Targeted Drugs
        • 7.2.3.3. Urinary Antispasmodics
        • 7.2.3.4. Uterine relaxants
        • 7.2.3.5. Others
      • 7.2.4. Global Genitourinary Drugs by: Disease Type (Value)
        • 7.2.4.1. Urinary Tract Infections
        • 7.2.4.2. STD
        • 7.2.4.3. Haematuria
        • 7.2.4.4. Urinary Incontinence
        • 7.2.4.5. Erectile dysfunction
        • 7.2.4.6. Others
      • 7.2.5. Global Genitourinary Drugs by: Distribution Chanel (Value)
        • 7.2.5.1. Direct
        • 7.2.5.2. Indirect
      • 7.2.6. Global Genitourinary Drugs by: Application (Value)
        • 7.2.6.1. Hospitals & Clinics
        • 7.2.6.2. Oncological Research Centres
      • 7.2.7. Global Genitourinary Drugs Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Genitourinary Drugs (Volume)
      • 7.3.1. Global Genitourinary Drugs by: Type (Volume)
        • 7.3.1.1. Urologicals
        • 7.3.1.2. Hormonal Therapy
        • 7.3.1.3. Gynecological
        • 7.3.1.4. Anti-infectives
      • 7.3.2. Global Genitourinary Drugs by: Application (Volume)
        • 7.3.2.1. Hospitals & Clinics
        • 7.3.2.2. Oncological Research Centres
      • 7.3.3. Global Genitourinary Drugs by: Drug Type (Volume)
        • 7.3.3.1. Hormonal Therapy
        • 7.3.3.2. Targeted Drugs
        • 7.3.3.3. Urinary Antispasmodics
        • 7.3.3.4. Uterine relaxants
        • 7.3.3.5. Others
      • 7.3.4. Global Genitourinary Drugs by: Disease Type (Volume)
        • 7.3.4.1. Urinary Tract Infections
        • 7.3.4.2. STD
        • 7.3.4.3. Haematuria
        • 7.3.4.4. Urinary Incontinence
        • 7.3.4.5. Erectile dysfunction
        • 7.3.4.6. Others
      • 7.3.5. Global Genitourinary Drugs by: Distribution Chanel (Volume)
        • 7.3.5.1. Direct
        • 7.3.5.2. Indirect
      • 7.3.6. Global Genitourinary Drugs by: Application (Volume)
        • 7.3.6.1. Hospitals & Clinics
        • 7.3.6.2. Oncological Research Centres
      • 7.3.7. Global Genitourinary Drugs Region
        • 7.3.7.1. South America
          • 7.3.7.1.1. Brazil
          • 7.3.7.1.2. Argentina
          • 7.3.7.1.3. Rest of South America
        • 7.3.7.2. Asia Pacific
          • 7.3.7.2.1. China
          • 7.3.7.2.2. Japan
          • 7.3.7.2.3. India
          • 7.3.7.2.4. South Korea
          • 7.3.7.2.5. Taiwan
          • 7.3.7.2.6. Australia
          • 7.3.7.2.7. Rest of Asia-Pacific
        • 7.3.7.3. Europe
          • 7.3.7.3.1. Germany
          • 7.3.7.3.2. France
          • 7.3.7.3.3. Italy
          • 7.3.7.3.4. United Kingdom
          • 7.3.7.3.5. Netherlands
          • 7.3.7.3.6. Rest of Europe
        • 7.3.7.4. MEA
          • 7.3.7.4.1. Middle East
          • 7.3.7.4.2. Africa
        • 7.3.7.5. North America
          • 7.3.7.5.1. United States
          • 7.3.7.5.2. Canada
          • 7.3.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Genitourinary Drugs: by Type(USD Million)
  • Table 2. Genitourinary Drugs Urologicals , by Region USD Million (2015-2020)
  • Table 3. Genitourinary Drugs Hormonal Therapy , by Region USD Million (2015-2020)
  • Table 4. Genitourinary Drugs Gynecological , by Region USD Million (2015-2020)
  • Table 5. Genitourinary Drugs Anti-infectives , by Region USD Million (2015-2020)
  • Table 6. Genitourinary Drugs: by Application(USD Million)
  • Table 7. Genitourinary Drugs Hospitals & Clinics , by Region USD Million (2015-2020)
  • Table 8. Genitourinary Drugs Oncological Research Centres , by Region USD Million (2015-2020)
  • Table 9. Genitourinary Drugs: by Drug Type(USD Million)
  • Table 10. Genitourinary Drugs Hormonal Therapy , by Region USD Million (2015-2020)
  • Table 11. Genitourinary Drugs Targeted Drugs , by Region USD Million (2015-2020)
  • Table 12. Genitourinary Drugs Urinary Antispasmodics , by Region USD Million (2015-2020)
  • Table 13. Genitourinary Drugs Uterine relaxants , by Region USD Million (2015-2020)
  • Table 14. Genitourinary Drugs Others , by Region USD Million (2015-2020)
  • Table 15. Genitourinary Drugs: by Disease Type(USD Million)
  • Table 16. Genitourinary Drugs Urinary Tract Infections , by Region USD Million (2015-2020)
  • Table 17. Genitourinary Drugs STD , by Region USD Million (2015-2020)
  • Table 18. Genitourinary Drugs Haematuria , by Region USD Million (2015-2020)
  • Table 19. Genitourinary Drugs Urinary Incontinence , by Region USD Million (2015-2020)
  • Table 20. Genitourinary Drugs Erectile dysfunction , by Region USD Million (2015-2020)
  • Table 21. Genitourinary Drugs Others , by Region USD Million (2015-2020)
  • Table 22. Genitourinary Drugs: by Distribution Chanel(USD Million)
  • Table 23. Genitourinary Drugs Direct , by Region USD Million (2015-2020)
  • Table 24. Genitourinary Drugs Indirect , by Region USD Million (2015-2020)
  • Table 25. Genitourinary Drugs: by Application(USD Million)
  • Table 26. Genitourinary Drugs Hospitals & Clinics , by Region USD Million (2015-2020)
  • Table 27. Genitourinary Drugs Oncological Research Centres , by Region USD Million (2015-2020)
  • Table 28. South America Genitourinary Drugs, by Country USD Million (2015-2020)
  • Table 29. South America Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 30. South America Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 31. South America Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 32. South America Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 33. South America Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 34. South America Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 35. Brazil Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 36. Brazil Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 37. Brazil Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 38. Brazil Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 39. Brazil Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 40. Brazil Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 41. Argentina Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 42. Argentina Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 43. Argentina Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 44. Argentina Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 45. Argentina Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 46. Argentina Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 47. Rest of South America Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 48. Rest of South America Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 49. Rest of South America Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 50. Rest of South America Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 51. Rest of South America Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 52. Rest of South America Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 53. Asia Pacific Genitourinary Drugs, by Country USD Million (2015-2020)
  • Table 54. Asia Pacific Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 55. Asia Pacific Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 56. Asia Pacific Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 57. Asia Pacific Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 58. Asia Pacific Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 59. Asia Pacific Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 60. China Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 61. China Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 62. China Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 63. China Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 64. China Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 65. China Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 66. Japan Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 67. Japan Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 68. Japan Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 69. Japan Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 70. Japan Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 71. Japan Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 72. India Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 73. India Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 74. India Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 75. India Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 76. India Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 77. India Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 78. South Korea Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 79. South Korea Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 80. South Korea Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 81. South Korea Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 82. South Korea Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 83. South Korea Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 84. Taiwan Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 85. Taiwan Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 86. Taiwan Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 87. Taiwan Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 88. Taiwan Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 89. Taiwan Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 90. Australia Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 91. Australia Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 92. Australia Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 93. Australia Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 94. Australia Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 95. Australia Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 96. Rest of Asia-Pacific Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 97. Rest of Asia-Pacific Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 98. Rest of Asia-Pacific Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 99. Rest of Asia-Pacific Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 100. Rest of Asia-Pacific Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 101. Rest of Asia-Pacific Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 102. Europe Genitourinary Drugs, by Country USD Million (2015-2020)
  • Table 103. Europe Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 104. Europe Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 105. Europe Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 106. Europe Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 107. Europe Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 108. Europe Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 109. Germany Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 110. Germany Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 111. Germany Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 112. Germany Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 113. Germany Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 114. Germany Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 115. France Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 116. France Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 117. France Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 118. France Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 119. France Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 120. France Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 121. Italy Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 122. Italy Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 123. Italy Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 124. Italy Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 125. Italy Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 126. Italy Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 127. United Kingdom Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 128. United Kingdom Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 129. United Kingdom Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 130. United Kingdom Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 131. United Kingdom Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 132. United Kingdom Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 133. Netherlands Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 134. Netherlands Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 135. Netherlands Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 136. Netherlands Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 137. Netherlands Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 138. Netherlands Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 139. Rest of Europe Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 140. Rest of Europe Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 141. Rest of Europe Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 142. Rest of Europe Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 143. Rest of Europe Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 144. Rest of Europe Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 145. MEA Genitourinary Drugs, by Country USD Million (2015-2020)
  • Table 146. MEA Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 147. MEA Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 148. MEA Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 149. MEA Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 150. MEA Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 151. MEA Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 152. Middle East Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 153. Middle East Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 154. Middle East Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 155. Middle East Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 156. Middle East Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 157. Middle East Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 158. Africa Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 159. Africa Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 160. Africa Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 161. Africa Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 162. Africa Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 163. Africa Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 164. North America Genitourinary Drugs, by Country USD Million (2015-2020)
  • Table 165. North America Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 166. North America Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 167. North America Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 168. North America Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 169. North America Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 170. North America Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 171. United States Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 172. United States Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 173. United States Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 174. United States Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 175. United States Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 176. United States Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 177. Canada Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 178. Canada Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 179. Canada Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 180. Canada Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 181. Canada Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 182. Canada Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 183. Mexico Genitourinary Drugs, by Type USD Million (2015-2020)
  • Table 184. Mexico Genitourinary Drugs, by Drug Type USD Million (2015-2020)
  • Table 185. Mexico Genitourinary Drugs, by Disease Type USD Million (2015-2020)
  • Table 186. Mexico Genitourinary Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 187. Mexico Genitourinary Drugs, by Cancer Type USD Million (2015-2020)
  • Table 188. Mexico Genitourinary Drugs, by Application USD Million (2015-2020)
  • Table 189. Genitourinary Drugs Sales: by Type(K Tons)
  • Table 190. Genitourinary Drugs Sales Urologicals , by Region K Tons (2015-2020)
  • Table 191. Genitourinary Drugs Sales Hormonal Therapy , by Region K Tons (2015-2020)
  • Table 192. Genitourinary Drugs Sales Gynecological , by Region K Tons (2015-2020)
  • Table 193. Genitourinary Drugs Sales Anti-infectives , by Region K Tons (2015-2020)
  • Table 194. Genitourinary Drugs Sales: by Application(K Tons)
  • Table 195. Genitourinary Drugs Sales Hospitals & Clinics , by Region K Tons (2015-2020)
  • Table 196. Genitourinary Drugs Sales Oncological Research Centres , by Region K Tons (2015-2020)
  • Table 197. Genitourinary Drugs Sales: by Drug Type(K Tons)
  • Table 198. Genitourinary Drugs Sales Hormonal Therapy , by Region K Tons (2015-2020)
  • Table 199. Genitourinary Drugs Sales Targeted Drugs , by Region K Tons (2015-2020)
  • Table 200. Genitourinary Drugs Sales Urinary Antispasmodics , by Region K Tons (2015-2020)
  • Table 201. Genitourinary Drugs Sales Uterine relaxants , by Region K Tons (2015-2020)
  • Table 202. Genitourinary Drugs Sales Others , by Region K Tons (2015-2020)
  • Table 203. Genitourinary Drugs Sales: by Disease Type(K Tons)
  • Table 204. Genitourinary Drugs Sales Urinary Tract Infections , by Region K Tons (2015-2020)
  • Table 205. Genitourinary Drugs Sales STD , by Region K Tons (2015-2020)
  • Table 206. Genitourinary Drugs Sales Haematuria , by Region K Tons (2015-2020)
  • Table 207. Genitourinary Drugs Sales Urinary Incontinence , by Region K Tons (2015-2020)
  • Table 208. Genitourinary Drugs Sales Erectile dysfunction , by Region K Tons (2015-2020)
  • Table 209. Genitourinary Drugs Sales Others , by Region K Tons (2015-2020)
  • Table 210. Genitourinary Drugs Sales: by Distribution Chanel(K Tons)
  • Table 211. Genitourinary Drugs Sales Direct , by Region K Tons (2015-2020)
  • Table 212. Genitourinary Drugs Sales Indirect , by Region K Tons (2015-2020)
  • Table 213. Genitourinary Drugs Sales: by Application(K Tons)
  • Table 214. Genitourinary Drugs Sales Hospitals & Clinics , by Region K Tons (2015-2020)
  • Table 215. Genitourinary Drugs Sales Oncological Research Centres , by Region K Tons (2015-2020)
  • Table 216. South America Genitourinary Drugs Sales, by Country K Tons (2015-2020)
  • Table 217. South America Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 218. South America Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 219. South America Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 220. South America Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 221. South America Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 222. South America Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 223. Brazil Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 224. Brazil Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 225. Brazil Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 226. Brazil Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 227. Brazil Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 228. Brazil Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 229. Argentina Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 230. Argentina Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 231. Argentina Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 232. Argentina Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 233. Argentina Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 234. Argentina Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 235. Rest of South America Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 236. Rest of South America Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 237. Rest of South America Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 238. Rest of South America Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 239. Rest of South America Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 240. Rest of South America Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 241. Asia Pacific Genitourinary Drugs Sales, by Country K Tons (2015-2020)
  • Table 242. Asia Pacific Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 243. Asia Pacific Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 244. Asia Pacific Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 245. Asia Pacific Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 246. Asia Pacific Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 247. Asia Pacific Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 248. China Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 249. China Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 250. China Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 251. China Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 252. China Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 253. China Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 254. Japan Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 255. Japan Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 256. Japan Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 257. Japan Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 258. Japan Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 259. Japan Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 260. India Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 261. India Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 262. India Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 263. India Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 264. India Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 265. India Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 266. South Korea Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 267. South Korea Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 268. South Korea Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 269. South Korea Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 270. South Korea Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 271. South Korea Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 272. Taiwan Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 273. Taiwan Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 274. Taiwan Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 275. Taiwan Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 276. Taiwan Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 277. Taiwan Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 278. Australia Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 279. Australia Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 280. Australia Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 281. Australia Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 282. Australia Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 283. Australia Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 284. Rest of Asia-Pacific Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 285. Rest of Asia-Pacific Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 286. Rest of Asia-Pacific Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 287. Rest of Asia-Pacific Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 288. Rest of Asia-Pacific Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 289. Rest of Asia-Pacific Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 290. Europe Genitourinary Drugs Sales, by Country K Tons (2015-2020)
  • Table 291. Europe Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 292. Europe Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 293. Europe Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 294. Europe Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 295. Europe Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 296. Europe Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 297. Germany Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 298. Germany Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 299. Germany Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 300. Germany Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 301. Germany Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 302. Germany Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 303. France Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 304. France Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 305. France Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 306. France Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 307. France Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 308. France Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 309. Italy Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 310. Italy Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 311. Italy Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 312. Italy Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 313. Italy Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 314. Italy Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 315. United Kingdom Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 316. United Kingdom Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 317. United Kingdom Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 318. United Kingdom Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 319. United Kingdom Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 320. United Kingdom Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 321. Netherlands Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 322. Netherlands Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 323. Netherlands Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 324. Netherlands Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 325. Netherlands Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 326. Netherlands Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 327. Rest of Europe Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 328. Rest of Europe Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 329. Rest of Europe Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 330. Rest of Europe Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 331. Rest of Europe Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 332. Rest of Europe Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 333. MEA Genitourinary Drugs Sales, by Country K Tons (2015-2020)
  • Table 334. MEA Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 335. MEA Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 336. MEA Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 337. MEA Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 338. MEA Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 339. MEA Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 340. Middle East Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 341. Middle East Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 342. Middle East Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 343. Middle East Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 344. Middle East Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 345. Middle East Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 346. Africa Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 347. Africa Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 348. Africa Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 349. Africa Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 350. Africa Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 351. Africa Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 352. North America Genitourinary Drugs Sales, by Country K Tons (2015-2020)
  • Table 353. North America Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 354. North America Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 355. North America Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 356. North America Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 357. North America Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 358. North America Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 359. United States Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 360. United States Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 361. United States Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 362. United States Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 363. United States Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 364. United States Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 365. Canada Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 366. Canada Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 367. Canada Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 368. Canada Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 369. Canada Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 370. Canada Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 371. Mexico Genitourinary Drugs Sales, by Type K Tons (2015-2020)
  • Table 372. Mexico Genitourinary Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 373. Mexico Genitourinary Drugs Sales, by Disease Type K Tons (2015-2020)
  • Table 374. Mexico Genitourinary Drugs Sales, by Distribution Chanel K Tons (2015-2020)
  • Table 375. Mexico Genitourinary Drugs Sales, by Cancer Type K Tons (2015-2020)
  • Table 376. Mexico Genitourinary Drugs Sales, by Application K Tons (2015-2020)
  • Table 377. Company Basic Information, Sales Area and Its Competitors
  • Table 378. Company Basic Information, Sales Area and Its Competitors
  • Table 379. Company Basic Information, Sales Area and Its Competitors
  • Table 380. Company Basic Information, Sales Area and Its Competitors
  • Table 381. Company Basic Information, Sales Area and Its Competitors
  • Table 382. Company Basic Information, Sales Area and Its Competitors
  • Table 383. Company Basic Information, Sales Area and Its Competitors
  • Table 384. Company Basic Information, Sales Area and Its Competitors
  • Table 385. Company Basic Information, Sales Area and Its Competitors
  • Table 386. Company Basic Information, Sales Area and Its Competitors
  • Table 387. Company Basic Information, Sales Area and Its Competitors
  • Table 388. Company Basic Information, Sales Area and Its Competitors
  • Table 389. Company Basic Information, Sales Area and Its Competitors
  • Table 390. Company Basic Information, Sales Area and Its Competitors
  • Table 391. Genitourinary Drugs: by Type(USD Million)
  • Table 392. Genitourinary Drugs Urologicals , by Region USD Million (2021-2026)
  • Table 393. Genitourinary Drugs Hormonal Therapy , by Region USD Million (2021-2026)
  • Table 394. Genitourinary Drugs Gynecological , by Region USD Million (2021-2026)
  • Table 395. Genitourinary Drugs Anti-infectives , by Region USD Million (2021-2026)
  • Table 396. Genitourinary Drugs: by Application(USD Million)
  • Table 397. Genitourinary Drugs Hospitals & Clinics , by Region USD Million (2021-2026)
  • Table 398. Genitourinary Drugs Oncological Research Centres , by Region USD Million (2021-2026)
  • Table 399. Genitourinary Drugs: by Drug Type(USD Million)
  • Table 400. Genitourinary Drugs Hormonal Therapy , by Region USD Million (2021-2026)
  • Table 401. Genitourinary Drugs Targeted Drugs , by Region USD Million (2021-2026)
  • Table 402. Genitourinary Drugs Urinary Antispasmodics , by Region USD Million (2021-2026)
  • Table 403. Genitourinary Drugs Uterine relaxants , by Region USD Million (2021-2026)
  • Table 404. Genitourinary Drugs Others , by Region USD Million (2021-2026)
  • Table 405. Genitourinary Drugs: by Disease Type(USD Million)
  • Table 406. Genitourinary Drugs Urinary Tract Infections , by Region USD Million (2021-2026)
  • Table 407. Genitourinary Drugs STD , by Region USD Million (2021-2026)
  • Table 408. Genitourinary Drugs Haematuria , by Region USD Million (2021-2026)
  • Table 409. Genitourinary Drugs Urinary Incontinence , by Region USD Million (2021-2026)
  • Table 410. Genitourinary Drugs Erectile dysfunction , by Region USD Million (2021-2026)
  • Table 411. Genitourinary Drugs Others , by Region USD Million (2021-2026)
  • Table 412. Genitourinary Drugs: by Distribution Chanel(USD Million)
  • Table 413. Genitourinary Drugs Direct , by Region USD Million (2021-2026)
  • Table 414. Genitourinary Drugs Indirect , by Region USD Million (2021-2026)
  • Table 415. Genitourinary Drugs: by Application(USD Million)
  • Table 416. Genitourinary Drugs Hospitals & Clinics , by Region USD Million (2021-2026)
  • Table 417. Genitourinary Drugs Oncological Research Centres , by Region USD Million (2021-2026)
  • Table 418. South America Genitourinary Drugs, by Country USD Million (2021-2026)
  • Table 419. South America Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 420. South America Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 421. South America Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 422. South America Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 423. South America Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 424. South America Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 425. Brazil Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 426. Brazil Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 427. Brazil Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 428. Brazil Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 429. Brazil Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 430. Brazil Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 431. Argentina Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 432. Argentina Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 433. Argentina Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 434. Argentina Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 435. Argentina Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 436. Argentina Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 437. Rest of South America Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 438. Rest of South America Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 439. Rest of South America Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 440. Rest of South America Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 441. Rest of South America Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 442. Rest of South America Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 443. Asia Pacific Genitourinary Drugs, by Country USD Million (2021-2026)
  • Table 444. Asia Pacific Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 445. Asia Pacific Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 446. Asia Pacific Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 447. Asia Pacific Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 448. Asia Pacific Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 449. Asia Pacific Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 450. China Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 451. China Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 452. China Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 453. China Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 454. China Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 455. China Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 456. Japan Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 457. Japan Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 458. Japan Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 459. Japan Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 460. Japan Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 461. Japan Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 462. India Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 463. India Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 464. India Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 465. India Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 466. India Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 467. India Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 468. South Korea Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 469. South Korea Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 470. South Korea Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 471. South Korea Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 472. South Korea Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 473. South Korea Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 474. Taiwan Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 475. Taiwan Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 476. Taiwan Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 477. Taiwan Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 478. Taiwan Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 479. Taiwan Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 480. Australia Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 481. Australia Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 482. Australia Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 483. Australia Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 484. Australia Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 485. Australia Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 486. Rest of Asia-Pacific Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 487. Rest of Asia-Pacific Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 488. Rest of Asia-Pacific Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 489. Rest of Asia-Pacific Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 490. Rest of Asia-Pacific Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 491. Rest of Asia-Pacific Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 492. Europe Genitourinary Drugs, by Country USD Million (2021-2026)
  • Table 493. Europe Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 494. Europe Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 495. Europe Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 496. Europe Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 497. Europe Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 498. Europe Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 499. Germany Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 500. Germany Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 501. Germany Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 502. Germany Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 503. Germany Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 504. Germany Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 505. France Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 506. France Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 507. France Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 508. France Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 509. France Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 510. France Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 511. Italy Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 512. Italy Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 513. Italy Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 514. Italy Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 515. Italy Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 516. Italy Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 517. United Kingdom Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 518. United Kingdom Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 519. United Kingdom Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 520. United Kingdom Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 521. United Kingdom Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 522. United Kingdom Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 523. Netherlands Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 524. Netherlands Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 525. Netherlands Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 526. Netherlands Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 527. Netherlands Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 528. Netherlands Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 529. Rest of Europe Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 530. Rest of Europe Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 531. Rest of Europe Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 532. Rest of Europe Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 533. Rest of Europe Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 534. Rest of Europe Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 535. MEA Genitourinary Drugs, by Country USD Million (2021-2026)
  • Table 536. MEA Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 537. MEA Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 538. MEA Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 539. MEA Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 540. MEA Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 541. MEA Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 542. Middle East Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 543. Middle East Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 544. Middle East Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 545. Middle East Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 546. Middle East Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 547. Middle East Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 548. Africa Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 549. Africa Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 550. Africa Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 551. Africa Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 552. Africa Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 553. Africa Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 554. North America Genitourinary Drugs, by Country USD Million (2021-2026)
  • Table 555. North America Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 556. North America Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 557. North America Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 558. North America Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 559. North America Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 560. North America Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 561. United States Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 562. United States Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 563. United States Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 564. United States Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 565. United States Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 566. United States Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 567. Canada Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 568. Canada Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 569. Canada Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 570. Canada Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 571. Canada Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 572. Canada Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 573. Mexico Genitourinary Drugs, by Type USD Million (2021-2026)
  • Table 574. Mexico Genitourinary Drugs, by Drug Type USD Million (2021-2026)
  • Table 575. Mexico Genitourinary Drugs, by Disease Type USD Million (2021-2026)
  • Table 576. Mexico Genitourinary Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 577. Mexico Genitourinary Drugs, by Cancer Type USD Million (2021-2026)
  • Table 578. Mexico Genitourinary Drugs, by Application USD Million (2021-2026)
  • Table 579. Genitourinary Drugs Sales: by Type(K Tons)
  • Table 580. Genitourinary Drugs Sales Urologicals , by Region K Tons (2021-2026)
  • Table 581. Genitourinary Drugs Sales Hormonal Therapy , by Region K Tons (2021-2026)
  • Table 582. Genitourinary Drugs Sales Gynecological , by Region K Tons (2021-2026)
  • Table 583. Genitourinary Drugs Sales Anti-infectives , by Region K Tons (2021-2026)
  • Table 584. Genitourinary Drugs Sales: by Application(K Tons)
  • Table 585. Genitourinary Drugs Sales Hospitals & Clinics , by Region K Tons (2021-2026)
  • Table 586. Genitourinary Drugs Sales Oncological Research Centres , by Region K Tons (2021-2026)
  • Table 587. Genitourinary Drugs Sales: by Drug Type(K Tons)
  • Table 588. Genitourinary Drugs Sales Hormonal Therapy , by Region K Tons (2021-2026)
  • Table 589. Genitourinary Drugs Sales Targeted Drugs , by Region K Tons (2021-2026)
  • Table 590. Genitourinary Drugs Sales Urinary Antispasmodics , by Region K Tons (2021-2026)
  • Table 591. Genitourinary Drugs Sales Uterine relaxants , by Region K Tons (2021-2026)
  • Table 592. Genitourinary Drugs Sales Others , by Region K Tons (2021-2026)
  • Table 593. Genitourinary Drugs Sales: by Disease Type(K Tons)
  • Table 594. Genitourinary Drugs Sales Urinary Tract Infections , by Region K Tons (2021-2026)
  • Table 595. Genitourinary Drugs Sales STD , by Region K Tons (2021-2026)
  • Table 596. Genitourinary Drugs Sales Haematuria , by Region K Tons (2021-2026)
  • Table 597. Genitourinary Drugs Sales Urinary Incontinence , by Region K Tons (2021-2026)
  • Table 598. Genitourinary Drugs Sales Erectile dysfunction , by Region K Tons (2021-2026)
  • Table 599. Genitourinary Drugs Sales Others , by Region K Tons (2021-2026)
  • Table 600. Genitourinary Drugs Sales: by Distribution Chanel(K Tons)
  • Table 601. Genitourinary Drugs Sales Direct , by Region K Tons (2021-2026)
  • Table 602. Genitourinary Drugs Sales Indirect , by Region K Tons (2021-2026)
  • Table 603. Genitourinary Drugs Sales: by Application(K Tons)
  • Table 604. Genitourinary Drugs Sales Hospitals & Clinics , by Region K Tons (2021-2026)
  • Table 605. Genitourinary Drugs Sales Oncological Research Centres , by Region K Tons (2021-2026)
  • Table 606. South America Genitourinary Drugs Sales, by Country K Tons (2021-2026)
  • Table 607. South America Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 608. South America Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 609. South America Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 610. South America Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 611. South America Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 612. South America Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 613. Brazil Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 614. Brazil Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 615. Brazil Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 616. Brazil Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 617. Brazil Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 618. Brazil Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 619. Argentina Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 620. Argentina Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 621. Argentina Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 622. Argentina Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 623. Argentina Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 624. Argentina Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 625. Rest of South America Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 626. Rest of South America Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 627. Rest of South America Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 628. Rest of South America Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 629. Rest of South America Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 630. Rest of South America Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 631. Asia Pacific Genitourinary Drugs Sales, by Country K Tons (2021-2026)
  • Table 632. Asia Pacific Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 633. Asia Pacific Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 634. Asia Pacific Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 635. Asia Pacific Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 636. Asia Pacific Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 637. Asia Pacific Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 638. China Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 639. China Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 640. China Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 641. China Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 642. China Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 643. China Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 644. Japan Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 645. Japan Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 646. Japan Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 647. Japan Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 648. Japan Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 649. Japan Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 650. India Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 651. India Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 652. India Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 653. India Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 654. India Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 655. India Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 656. South Korea Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 657. South Korea Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 658. South Korea Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 659. South Korea Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 660. South Korea Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 661. South Korea Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 662. Taiwan Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 663. Taiwan Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 664. Taiwan Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 665. Taiwan Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 666. Taiwan Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 667. Taiwan Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 668. Australia Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 669. Australia Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 670. Australia Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 671. Australia Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 672. Australia Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 673. Australia Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 674. Rest of Asia-Pacific Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 675. Rest of Asia-Pacific Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 676. Rest of Asia-Pacific Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 677. Rest of Asia-Pacific Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 678. Rest of Asia-Pacific Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 679. Rest of Asia-Pacific Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 680. Europe Genitourinary Drugs Sales, by Country K Tons (2021-2026)
  • Table 681. Europe Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 682. Europe Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 683. Europe Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 684. Europe Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 685. Europe Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 686. Europe Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 687. Germany Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 688. Germany Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 689. Germany Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 690. Germany Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 691. Germany Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 692. Germany Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 693. France Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 694. France Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 695. France Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 696. France Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 697. France Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 698. France Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 699. Italy Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 700. Italy Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 701. Italy Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 702. Italy Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 703. Italy Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 704. Italy Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 705. United Kingdom Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 706. United Kingdom Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 707. United Kingdom Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 708. United Kingdom Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 709. United Kingdom Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 710. United Kingdom Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 711. Netherlands Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 712. Netherlands Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 713. Netherlands Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 714. Netherlands Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 715. Netherlands Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 716. Netherlands Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 717. Rest of Europe Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 718. Rest of Europe Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 719. Rest of Europe Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 720. Rest of Europe Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 721. Rest of Europe Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 722. Rest of Europe Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 723. MEA Genitourinary Drugs Sales, by Country K Tons (2021-2026)
  • Table 724. MEA Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 725. MEA Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 726. MEA Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 727. MEA Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 728. MEA Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 729. MEA Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 730. Middle East Genitourinary Drugs Sales, by Type K Tons (2021-2026)
  • Table 731. Middle East Genitourinary Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 732. Middle East Genitourinary Drugs Sales, by Disease Type K Tons (2021-2026)
  • Table 733. Middle East Genitourinary Drugs Sales, by Distribution Chanel K Tons (2021-2026)
  • Table 734. Middle East Genitourinary Drugs Sales, by Cancer Type K Tons (2021-2026)
  • Table 735. Middle East Genitourinary Drugs Sales, by Application K Tons (2021-2026)
  • Table 736. Africa Genitourinary Drugs Sales, by Type K Tons (2021-2026)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Genitourinary Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Genitourinary Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Genitourinary Drugs: by Drug Type USD Million (2015-2020)
  • Figure 7. Global Genitourinary Drugs: by Disease Type USD Million (2015-2020)
  • Figure 8. Global Genitourinary Drugs: by Distribution Chanel USD Million (2015-2020)
  • Figure 9. Global Genitourinary Drugs: by Application USD Million (2015-2020)
  • Figure 10. South America Genitourinary Drugs Share (%), by Country
  • Figure 11. Asia Pacific Genitourinary Drugs Share (%), by Country
  • Figure 12. Europe Genitourinary Drugs Share (%), by Country
  • Figure 13. MEA Genitourinary Drugs Share (%), by Country
  • Figure 14. North America Genitourinary Drugs Share (%), by Country
  • Figure 15. Global Genitourinary Drugs: by Type K Tons (2015-2020)
  • Figure 16. Global Genitourinary Drugs: by Application K Tons (2015-2020)
  • Figure 17. Global Genitourinary Drugs: by Drug Type K Tons (2015-2020)
  • Figure 18. Global Genitourinary Drugs: by Disease Type K Tons (2015-2020)
  • Figure 19. Global Genitourinary Drugs: by Distribution Chanel K Tons (2015-2020)
  • Figure 20. Global Genitourinary Drugs: by Application K Tons (2015-2020)
  • Figure 21. South America Genitourinary Drugs Share (%), by Country
  • Figure 22. Asia Pacific Genitourinary Drugs Share (%), by Country
  • Figure 23. Europe Genitourinary Drugs Share (%), by Country
  • Figure 24. MEA Genitourinary Drugs Share (%), by Country
  • Figure 25. North America Genitourinary Drugs Share (%), by Country
  • Figure 26. Global Genitourinary Drugs share by Players 2020 (%)
  • Figure 27. Global Genitourinary Drugs share by Players (Top 3) 2020(%)
  • Figure 28. Global Genitourinary Drugs share by Players (Top 5) 2020(%)
  • Figure 29. BCG Matrix for key Companies
  • Figure 30. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 32. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 34. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 36. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 38. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 40. Hoffmann-La Roche Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Hoffmann-La Roche Ltd. (United States) Revenue: by Geography 2020
  • Figure 42. Astra Zeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 43. Astra Zeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 44. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 45. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 46. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 47. Celgene (United States) Revenue: by Geography 2020
  • Figure 48. Eli Lilly & Co (United States) Revenue, Net Income and Gross profit
  • Figure 49. Eli Lilly & Co (United States) Revenue: by Geography 2020
  • Figure 50. Cadila Healthcare Limited (India) Revenue, Net Income and Gross profit
  • Figure 51. Cadila Healthcare Limited (India) Revenue: by Geography 2020
  • Figure 52. Dr. Reddy’s Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 53. Dr. Reddy’s Laboratories Ltd. (India) Revenue: by Geography 2020
  • Figure 54. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 55. Amgen (United States) Revenue: by Geography 2020
  • Figure 56. AQVIDA GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 57. AQVIDA GmbH (Germany) Revenue: by Geography 2020
  • Figure 58. Global Genitourinary Drugs: by Type USD Million (2021-2026)
  • Figure 59. Global Genitourinary Drugs: by Application USD Million (2021-2026)
  • Figure 60. Global Genitourinary Drugs: by Drug Type USD Million (2021-2026)
  • Figure 61. Global Genitourinary Drugs: by Disease Type USD Million (2021-2026)
  • Figure 62. Global Genitourinary Drugs: by Distribution Chanel USD Million (2021-2026)
  • Figure 63. Global Genitourinary Drugs: by Application USD Million (2021-2026)
  • Figure 64. South America Genitourinary Drugs Share (%), by Country
  • Figure 65. Asia Pacific Genitourinary Drugs Share (%), by Country
  • Figure 66. Europe Genitourinary Drugs Share (%), by Country
  • Figure 67. MEA Genitourinary Drugs Share (%), by Country
  • Figure 68. North America Genitourinary Drugs Share (%), by Country
  • Figure 69. Global Genitourinary Drugs: by Type K Tons (2021-2026)
  • Figure 70. Global Genitourinary Drugs: by Application K Tons (2021-2026)
  • Figure 71. Global Genitourinary Drugs: by Drug Type K Tons (2021-2026)
  • Figure 72. Global Genitourinary Drugs: by Disease Type K Tons (2021-2026)
  • Figure 73. Global Genitourinary Drugs: by Distribution Chanel K Tons (2021-2026)
  • Figure 74. Global Genitourinary Drugs: by Application K Tons (2021-2026)
  • Figure 75. South America Genitourinary Drugs Share (%), by Country
  • Figure 76. Asia Pacific Genitourinary Drugs Share (%), by Country
  • Figure 77. Europe Genitourinary Drugs Share (%), by Country
  • Figure 78. MEA Genitourinary Drugs Share (%), by Country
  • Figure 79. North America Genitourinary Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb (United States)
  • Johnson & Johnson (United States)
  • Pfizer Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Hoffmann-La Roche Ltd. (United States)
  • Astra Zeneca (United Kingdom)
  • AbbVie Inc. (United States)
  • Celgene (United States)
  • Eli Lilly & Co (United States)
  • Cadila Healthcare Limited (India)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Amgen (United States)
  • AQVIDA GmbH (Germany)
Select User Access Type

Key Highlights of Report


Apr 2021 221 Pages 56 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Genitourinary Drugs Quantitative research analysis
Global Genitourinary Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Genitourinary Drugs Report?

Have a Query? Click Here

Other Related Reports

Grass Pollen Allergy Drug Comprehensive Study by Type (BM-32, Pollinex Quattro Grass, Others), Application (Home Use, Hospital, Research Center) Players and Region - Global Market Outlook to 2027
$ 3500
Amlodipine Besylater Comprehensive Study by Type (2.5mg, 5mg, 10mg), Application (High Blood Pressure, Heart Disease), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies...
$ 3650
Mouth Ulcers Drugs Comprehensive Study by Type (Corticosteroid , Anesthetic , Analgesic , Antihistamine , Antimicrobial), Application (Adults, Kids), Indication Type (Aphthous Stomatitis, Oral Lichen...
$ 3650
Sterile Medical Packaging Comprehensive Study by Type (Thermoform trays, Sterile bottles & containers, Vials & ampoules, Pre-fillable inhalers, Sterile closures, Pre-filled syringes, Blister & clamsh...
$ 3750
Specialty Pharmaceutical Comprehensive Study by Application (Hospitals, Specialty Pharmacies, Others (Mail Order)), Route of administration (Oral, Parenteral, Transdermal), Therapeutic area (Oncolo...
$ 3650
Anticoagulant Drug Comprehensive Study by Type (Coumarins & Indandiones, Factor Xa Inhibitors, Heparins, Thrombin Inhibitors), Application (Atrial Fibrillation, Deep Vein Thrombosis, Artificial Heart...
$ 3750